FibroGen Inc stock (US3156631046): volatility after Nasdaq delisting and Kynbio merger plans

FibroGen Inc faces a turbulent transition after its delisting from Nasdaq and agreement to merge into Kynbio Therapeutics, leaving shareholders with questions about the future structure and value of their investment.

FibroGen Inc is in the middle of a far-reaching transformation that includes a delisting from the Nasdaq exchange and plans to combine with Kynbio Therapeutics, a move that significantly changes how existing shareholders are exposed to the company’s drug pipeline, according to a corporate actions overview updated in April 2025 by Robinhood as of 04/30/2025. The change included a trading symbol transition to KYNB and marked the end of FibroGen’s long-standing presence on the Nasdaq Global Select Market, according to a delisting notice published in late 2024 by Nasdaq as of 12/30/2024.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: FibroGen Inc
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: United States
• Core markets: Anemia, fibrosis and oncology therapies
• Key revenue drivers: Royalties and milestone payments from anemia drug collaborations
• Home exchange/listing venue: Formerly Nasdaq; transitioned to KYNB following corporate reorganization
• Trading currency: US dollar (USD)

FibroGen Inc: core business model

FibroGen Inc has historically operated as a clinical-stage and commercial-stage biopharmaceutical company focused on developing and commercializing therapies for anemia, fibrotic diseases and oncology indications. Its most prominent program has been roxadustat, an oral small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase that is designed to treat anemia in patients with chronic kidney disease. The company has pursued a partnership-heavy business model, relying on large pharmaceutical partners to commercialize roxadustat in major markets such as China, Japan and parts of Europe.

In financial terms, FibroGen’s revenue mix has largely consisted of collaboration payments, milestone receipts and royalties from partner sales, supplemented by some direct product revenue in select territories. This structure means that the company’s top line is sensitive to partner performance, regulatory outcomes and pricing decisions in key markets. For example, regulatory approvals of roxadustat in China and Japan created an initial ramp-up in royalties, while setbacks in the US regulatory process reduced expectations for near-term direct product sales.

Beyond roxadustat, FibroGen has advanced a portfolio of investigational compounds targeting pathways involved in fibrosis and cancer. These programs include antibodies and small molecules designed to influence fibrogenesis and tumor microenvironments. As is typical for biotechnology companies, most of these potential products are in Phase 1 or Phase 2 development, meaning they are several years away from possible commercialization and carry significant clinical and regulatory risk. The combination of a marketed collaboration asset and earlier-stage pipeline is a common structure among mid-cap biotech firms listed in the US market.

Over the years, FibroGen’s business model has also been characterized by substantial investment in research and development. The company has consistently allocated a majority of its operating expenses to R&D, reflecting the long timelines and high failure rates associated with drug discovery. That in turn has led to recurring net losses, which have been financed through equity offerings and partnership payments. For US investors, this pattern is familiar among biotech issuers: the path to value creation often runs through dilution before any sustainable profit can be generated.

Main revenue and product drivers for FibroGen Inc

Roxadustat has been the central economic driver for FibroGen Inc. The company entered into major collaborations with Astellas Pharma and AstraZeneca to develop and commercialize the drug in various territories, receiving upfront payments, development milestones and royalties tied to net sales. In China, roxadustat has been approved for anemia associated with chronic kidney disease, creating a growing base of royalty revenue that helped stabilize FibroGen’s income statement, according to the company’s full-year 2023 earnings release published in March 2024 by FibroGen investor relations as of 03/05/2024. However, revenue remained concentrated in a limited number of markets and partners, increasing exposure to regional pricing and reimbursement decisions.

In the US and Europe, the commercial outlook for roxadustat has been more uncertain. Regulatory reviews have involved detailed scrutiny of cardiovascular safety data, which in turn has affected partner strategies and timelines for potential launches. When regulatory agencies request additional analyses or impose restrictions on labeling, the projected peak sales for a drug can be revised downward, and that dynamic has periodically influenced investor sentiment around FibroGen’s stock. Such changes reverberate through royalties and milestones that the company can expect from its agreements.

FibroGen has attempted to diversify its revenue base by advancing other programs, including pamrevlumab, an antibody targeting connective tissue growth factor for fibrotic diseases such as idiopathic pulmonary fibrosis and certain oncology indications. Clinical trial outcomes have been mixed, with some studies not meeting primary endpoints, according to development updates published during 2022 and 2023 by PR Newswire as of 08/04/2023. These setbacks have reduced expectations for near-term diversification of revenue, reinforcing the dependence on roxadustat and emphasizing the binary nature of clinical catalysts.

As the relationship with Kynbio Therapeutics has developed, investors have increasingly focused on how the combined entity might reshape the revenue profile. Transactions that involve legacy biotech pipelines being merged into new corporate structures can lead to asset prioritization, divestitures or out-licensing. For holders of FibroGen stock transitioning into KYNB exposure, the key questions revolve around which programs remain core, what level of R&D spending the new entity will commit to, and how future royalties or milestones related to existing collaborations are treated within the merger framework. Such details typically emerge in proxy statements and transaction filings that outline the mechanics of share exchanges and post-merger capitalization.

Industry trends and competitive position

The broader biopharmaceutical industry in which FibroGen operates is undergoing significant consolidation and strategic refocusing. Large pharmaceutical companies continue to seek late-stage or de-risked assets through acquisitions and partnerships, while smaller biotech firms often depend on the capital markets for funding. The volatility of interest rates and risk appetite in US equity markets directly affects valuations, as investors reassess the cost of capital for long-duration R&D projects. For a company like FibroGen, which has relied on partnerships and periodic capital raises, shifts in financing conditions can influence strategic decisions such as mergers, licensing deals or pipeline reprioritization.

In the anemia and nephrology segments, competition is intense. Traditional injectable erythropoiesis-stimulating agents remain entrenched, while new oral therapies from multiple developers aim to gain share. Health systems and payers are increasingly focused on demonstrating clear clinical and economic advantages before granting broad access to premium-priced therapies. That environment favors companies that can generate strong real-world evidence and negotiate effectively with payers. For FibroGen’s historical roxadustat collaborations, the pace of uptake depends not only on regulatory approvals but also on formulary positioning and reimbursement outcomes in each geography.

Fibrosis and oncology, the other main focus areas for FibroGen’s pipeline, are also densely populated with competitors ranging from small biotech innovators to global pharma leaders. Many mechanisms of action are still being validated in late-stage trials, and the bar for demonstrating clinical benefit is high. Regulatory agencies expect robust survival or functional outcomes, particularly when existing standard-of-care therapies are available. This competitive backdrop means that any new entity resulting from FibroGen’s transition to Kynbio Therapeutics would need to clearly articulate how its assets stand out in terms of efficacy, safety and patient convenience.

Why FibroGen Inc matters for US investors

For US investors, FibroGen Inc represents a case study in the opportunities and risks of mid-cap biotechnology investing. The company’s journey from a prominent Nasdaq listing to a corporate reorganization and transition toward Kynbio Therapeutics illustrates how quickly the narrative around a biotech stock can shift. On one hand, the presence of a marketed asset generating royalties offers a tangible revenue stream that many early-stage biotech peers lack. On the other hand, the dependence on a small number of products and partners makes the equity sensitive to single-asset developments such as trial readouts, label changes or reimbursement decisions.

Biotech stocks frequently exhibit high volatility around clinical and regulatory catalysts, and FibroGen has been no exception. Trading volumes have spiked following trial announcements and partnership updates, reflecting the market’s attempt to rapidly incorporate new information into valuations. For US-based retail investors in particular, understanding the timing and nature of such catalysts is crucial for contextualizing price movements. The transition to the KYNB structure adds an additional layer of complexity, as investors must track not only clinical updates but also corporate actions, share exchange ratios and listing details.

In terms of portfolio construction, exposure to a company like FibroGen is often considered part of a higher-risk, higher-potential return satellite allocation rather than a core holding. The biotech sector tends to be less correlated with traditional economic cycles and more driven by scientific and regulatory milestones. That characteristic can provide diversification benefits within a broader US equity portfolio, but it also means that idiosyncratic risk is elevated. The evolving story around FibroGen and Kynbio underscores the importance of continuously monitoring company disclosures, clinical trial registries and regulatory announcements when evaluating biotech positions.

Conclusion

FibroGen Inc is navigating a pivotal transition that moves the company away from its traditional standalone Nasdaq listing toward a new corporate configuration associated with Kynbio Therapeutics, following a symbol change to KYNB that was recorded in a corporate actions tracker updated in 2025 by Robinhood as of 04/30/2025. The legacy business model centered on roxadustat royalties and a high-risk development pipeline remains, but the ownership and listing structure for shareholders is evolving. For US investors observing the stock, the key considerations include how the new entity prioritizes assets, manages R&D spending and communicates around future catalysts. While the biotechnology sector continues to offer substantial upside for successful drug developers, it also exposes investors to significant clinical, regulatory and financing uncertainties, all of which are evident in FibroGen’s ongoing transformation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.